Anterios

Allergan Acquires Anterios, Expands Neurotoxin Pipeline

Allergan has announced its acquisition of Anterios, a clinical-stage biopharmaceutical company developing a next-generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an up-front payment of $90 million and potential development and commercialization milestone payments related to NDS, Anterios’ proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without injection.

Anterios Announces Development Of Next-Generation Injectable Neurotoxin

Anterios Announces Development Of Next-Generation Injectable Neurotoxin

Anterios, a privately held aesthetic medicine and medical dermatology biopharmaceutical company, has announced development of a next-generation injectable botulinum toxin product, AI-09. Unlike currently commercialized botulinum toxin products that require reconstitution prior to injection, AI-09 will be packaged as a ready-to-use injectable liquid and is a complementary product to the company's topical botulinum prescription Phase IIb product ANT-1207, which is being developed for wrinkles, hyperhidrosis (excessive sweating) and acne.

Topical Botulinum Toxin Moves Forward With New Funding

Topical Botulinum Toxin Moves Forward With New Funding

Anterios, a privately held aesthetic medicine and medical dermatology biopharmaceutical company, has received $8.5 million in corporate financing, which will be used to further development of its patented topical botulinum toxin type A treatment, ANT-1207. Anterios is currently conducting Phase 2b clinical trials of ANT-1207 for clinical indications, including the treatment of lateral canthal lines, hyperhidrosis and acne. Anterios previously completed multi-center, double-blind, randomized, controlled, dose-escalation studies for each indication.